Skip to main
PASG
PASG logo

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio Inc is strategically positioned to capitalize on the development of groundbreaking therapies for rare CNS disorders, with an emphasis on early intervention which enhances the potential benefits of its lead product, PBFT02. The positive interim data from the June '25 upliFT-D study highlights the durability of Dose 1, exhibiting sustained increases in key biomarkers indicating a favorable response, which could lead to accelerated approval pathways. Moreover, the trial's concurrent enrollment of Cohort 3 aims to expedite progress, strengthening the company's prospects for successful outcomes in both the clinical and regulatory arenas.

Bears say

Passage Bio Inc. faces significant financial risks primarily due to potential clinical delays and safety concerns associated with its gene therapy programs PBGM01 and PBFT02, which could adversely affect market sentiment and lead to downward revisions in financial forecasts. The company is exposed to heightened regulatory risks and the challenges of developing sufficient manufacturing capacity, which could further constrain growth projections. Past experiences with gene therapy products underscore the unpredictability in safety and efficacy outcomes, creating a precarious environment for Passage Bio's future financial performance.

PASSAGE BIO (PASG) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Strong Buy based on their latest research and market trends.

According to 4 analysts, PASSAGE BIO (PASG) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.